Pharmacodynamic interactions of the redox modulating amino acids L-arginine and taurine with pleiotropic anti-oxidants
Abstract
М) in molar ratios of 1:1-1:100 (CI = 0.56-0.04). The components of such combinations are not only complementary another absolute anti-radical spectrum and biological activity, but also accelerate the radical interaction with each other and are considered as the basis for developing new cytoprotective and antioxidant drugs. It is also shown that the inclusion of an additional component in the synergistic combination can alter the character of the components interaction to antagonism and the resultant biological effect of the combination, which in turn indicates the urgent need for a comprehensive pre-clinical study of any drugs combinations.
References
1. Effects of arginine, L-alanyl-L-glutamine or taurine on neutrophil (PMN) free amino acid profiles and immune functions in vitro / J. Muhling [et al.] // Amino Acids. - 2002. - Vol. 22, N 1. - P. 39-53.
2. Заволовская, Л. И. Клиническая эффективность тауфона в комбинированном лечении больных с хронической недостаточностью кровообращения / Л. И. Заволовская, Е. П. Елизарова, В. А. Орлов // Эксперим. и клин. фармакол. -1995. - Т. 58. - С. 29-32.
3. Шестакова, М. В. Опыт применения дибикора при сахарном диабете второго типа / М. В. Шестакова, Л. А. Чугунова, М. Ш. Шахалова // Сахарный диабет. - 2007. - № 1. - С. 30-31.
4. Anthrayose, C. V. Studies on protein and taurine in normal, senile and diabetic cataractous human lenses / C. V. Anthrayose, S. Shashidhar // Indian J. Physiol. Pharmacol. - 2004. - Vol. 48, N 3. - Р. 357-360.
5. The effect of taurine on the toll-like receptors/nuclear factor kappa B (TLRs/NF-кВ) signaling pathway in Streptococcus uberis-induced mastitis in rats / J. Miaoa [et al.] // Int. Immunopharm. - 2011. - Vol. 11. - Р. 1740-1746.
6. Chou, T.-Ch. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies / T.-Ch. Chou // Pharmacol. Rev. - 2006. - Vol. 58. - Р. 621-681.
7. Bizunok, N. A. Theory of pleiotropic action of biologically active compounds and medicines - basic principles and practical application / N. A. Bizunok // Open J. of Clin. Diagnostics. - 2013. - Vol. 3, N 3. - P. 94-104.
8. Бизунок, Н. А. Плейотропное действие модуляторов клеточных функций на макрофагальную генерацию активных форм кислорода при FcR-зависимом фагоцитозе / Н. А. Бизунок // Мед. журн. - 2013. - № 2. - С. 44-47.
9. Дубовик, Б. В. Синергичные иммунотропные взаимодействия компонента красного вина транс-ресвератрола, антиоксиданта аскорбата и гормона мелатонина на модели респираторного взрыва макрофагов / Б. В. Дубовик, Н. А. Бизунок // Мед. журн. - 2011. - № 3. - С. 52-61.
10. Opie, L. H. The red wine hypothesis: from concepts to protective signalling molecules / L. H. Opie, S. Lecour // Eur. Heart J. - 2007. - Vol. 28. - P. 1683-1693.
11. Resveratrol attenuates oxLDL-stimulated NADPH oxidase activity and protects endothelial cells from oxidative functional damages / Shu-Er Chow [et al.] // J. Appl. Physiol. - 2007. - Vol. 102. - P. 1520-1527.
12. Ximenes, V. F. Superoxide-dependent oxidation of melatonin by myeloperoxidase // V. F. Ximenes [et al.] // J. Biol. Chem. - 2005. - Vol. 280, N 46. - Р. 38160-38169.
13. Melatonin as an antioxidant: biochemical mechanisms and pathophysiological implications in humans / R. J. Reiter [et al.] // Acta Biochim. Polonica. - 2003. - Vol. 50, N 4. - P. 1129-1146.
14. Зозуля, Ю. А. Свободнорадикальное окисление и антиоксидантная защита при патологии головного мозга / Ю. А. Зозуля, В. А. Барабой, Д. А. Сутковой. - М.: Знание-М, 2000. - 344 с.
15. Melatonin inhibits expression of the inducible NO synthase II in liver and lung and prevents endotoxemia in lipopoly-saccharide-induced multiple organ dysfunction syndrome in rats / E. Crespo [et al.] // FASEB J. - 1999. - Vol. 13, N 12. -P. 1537-1546.
16. Melatonin inhibits expression of the inducible isoform of nitric oxide synthase in murine macrophages: role of inhibition of NFkB activation / E. Gilad [et al.] // FASEB J. - 1998. - Vol. 12. - P. 685-693.
17. International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, Classification, and Pharmacology of G Protein-Coupled Melatonin Receptors / M. L. Dubocovich [et al.] // Pharmacol. Rev. - 2010. - Vol. 62. - Р. 343-380.
18. Expression of membrane and nuclear melatonin receptor mRNA and protein in the mouse immune system / A. Car-rillo-Vico [et al.] // Cell. and Mol. Life Sci. (CMLS). - 2003. - Vol. 60, N 10. - P. 2272-2278.
19. Guerrero, J. M. Melatonin-immune system relationships / J. M. Guerrero, R. J. Reiter // Curr. Top. Med. Chem. -2002. - Vol. 2. - Р. 167-179.
20. Correlation between nuclear melatonin receptor expression and enhanced cytokine production in human lymphocytic and monocytic cell lines / S. Garcia-Maurmo [et al.] // J. Pineal Res. - 2000. - Vol. 29, N 3. - P. 129-137.
21. Free radical mediated molecular damage: mechanisms of melatonin's protective actions in the central nervous system / R. J. Reiter [et al.] // Ann. N. Y. Acad. Sci. - 2001. - Vol. 939, N 1. - P. 200-215.
22. Functional and analytical evidence for scavenging of oxygen radicals by L-arginine / A. Lass [et al.] // Mol. pharmacol. - 2002. - Vol. 61, N 5. - P. 1081-1088.
23. Taurine chloramine inhibits inducible nitric oxide synthase and TNF-a gene expression in activated alveolar macro-phages: decreased NF-kB activation and IkB kinase activity / M. Barua [et al.] // J. Immunol. - 2001. - Vol. 167. - P. 2275-2281.
24. The antioxidant action of taurine, hypotaurine, and their metabolic precursors / O. I. Aruoma [et al.] // Biochem. J. -1988. - Vol. 256. - P. 251-255.
25. Jones, D. P. Radical-free biology of oxidative stress / D. P. Jones // Am. J. Physiol. Cell Physiol. - 2008. - Vol. 295. -Р. C849-C868.
26. Копелевич, В. М. Витаминоподобные соединения L-карнитин и ацетил^-карнитин: от биохим. исслед. к мед. применению / В. М. Копелевич // Укр. биохим. журн. - 2005. - Т. 77, № 4. - С. 30-50.
27. Ames, B. N. Delaying the mitochondrial decay of aging with acetylcarnitine / B. N. Ames, J. Liu // Ann. N. Y. Acad. Sci. - 2004. - Vol. 1033. - P. 108-116.
28. Acetyl-L-carnitine ameliorates hypobaric hypoxic impairment and spatial memory deficits in rats / K. Barhwal [et al.] // Eur. J. Pharmacol. - 2007. - Vol. 570. - P. 97-107.
29. Effect of ICV taurine on the impairment of learning, convulsions and death caused by hypoxia / M. Malcangio [et al.] // Psychopharmacology. - 1989. - Vol. 98, N 3. - P. 316-320.
30. Saransaari, P. Taurine and neural cell damage / P. Saransaari, S. S. Oja // Amino Acids. - 2000. - Vol. 19, N 3-4. - P. 509-526.
31. Vohra, B. P. Improvement of impaired memory in mice by taurine / B. P. Vohra, X. Hui // Neural Plast. - 2000. - Vol. 7, N 4. - P. 245-259.
32. Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-L-carni-tine / G. Bianchi [et al.] // Eur. J. Cancer. - 2005. - Vol. 41. - P. 1746-1750.
33. Acetyl-L-carnitine administration increases insulin-like growth factor 1 levels in asymptomatic HIV-1-infected subjects correlation with its suppressive effect on lymphocyte apoptosis and ceramide generation / L. Di Marzio [et al.] // Clin. Immunol. - 1999. - Vol. 92. - P. 103-110.
34. Kim, C. Production of reactive oxygen and nitrogen species in phagocytes is regulated by taurine chloramines / C. Kim, Y. N. Cha. // Adv. Exp. Med. Biol. - 2009. - Vol. 643. - P. 463-472.
35. Antimicrobial and cytotoxic activity of hypochlorous acid: interactions with taurine and nitrite / J. Marcinkiewicz [et al.] // J. Inflamm. Res. - 2000. - Vol. 49, N 6. - P. 280-289.
36. Acute effects of acetyl-L-carnitine on regional cerebral blood flow in patients with brain ischemia / G. Rosadini [et al.] // Int. J. Clin. Pharmacol. Res. - 1990. - Vol. 10. - P. 123-128.
37. Acetylcarnitine and cellular stress response: roles in nutritional redox homeostasis and regulation of longevity genes / V. Calabrese [et al.] // J. Nutr. Biochem. - 2006. - Vol. 17, N 2. - P. 73-88.
38. Antioxidant role and subcellular location of hypotaurine and taurine in human neutrophils / T. R. Green [et al.] // Biochim. Biophys. Acta. - 1991. - Vol. 1073. - P. 91-97.
39. Reactivity of taurine with aldehydes and its physiological role / M. Ogasawara [et al.] // Chem. Pharm. Bull. - 1993. -Vol. 41. - P. 2172-2175.
40. The sympathetic nerve - an integrative interface between two supersysrems: the brain and the immune system / I. J. Elenkov [et al.] // Pharmacol. Rev. - 2000. - Vol. 52. - P. 595-638.
41. Wu, J.-Y. Role of taurine in the central nervous system / J.-Y. Wu, H. Prentice // J. Biomed. Sci. - 2010. - Vol. 17 (Suppl. 1). - Режим доступа: http://www.jbiomedsci.com/content/pdf/1423-0127-17-S1-S1.pdf. - Дата доступа: 24.08.2010.
Review
For citations:
Bizunok N.A. Pharmacodynamic interactions of the redox modulating amino acids L-arginine and taurine with pleiotropic anti-oxidants. Proceedings of the National Academy of Sciences of Belarus, Medical series. 2015;(4):68-84. (In Russ.)
Views: 1345
Email this article 